Pharmaceutical

Lantheus acquires radiopharma CDMO Evergreen for up to $1bn

The deal includes an upfront payment of $250m, with the potential for an additional $752.5m in milestone payments.

Jan 30, 2025 - 06:00
Lantheus acquires radiopharma CDMO Evergreen for up to $1bn
The deal includes an upfront payment of $250m, with the potential for an additional $752.5m in milestone payments.
Read the original article

Tags:

Previous Article

FDA expands Enhertu approval to include HER2-ultralow breast cancer patients

Next Article

Novo Nordisk secures FDA approval for Ozempic in diabetes with CKD

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

MSD secures worldwide license for LaNova’s LM-299

MSD secures worldwide license for LaNova’s LM-299

Nov 15, 2024

STAT+: Pharmalittle: White House drug-shortage task force brainstorms fixes; U.S. pharma layoffs are ballooning

STAT+: Pharmalittle: White House drug-shortage task for...

Aug 5, 2023

Signal: Illumina under investigation by SEC over $8bn Grail acquisition

Signal: Illumina under investigation by SEC over $8bn G...

Aug 16, 2023